Research programme: hyaluronan mediated motility receptors targeted therapeutics - Novare Pharmaceuticals
Alternative Names: HMMR-protein-target - Novare Pharmaceuticals; Intracellular-hyaluronic-acid-binding-protein-target - Novare Pharmaceuticals; Receptors for hyaluronan mediated motility targeting therapeutics - Novare Pharmaceuticals; RHAMM-binding peptides-Novare Pharmaceuticals; RHAMM-protein-target - Novare PharmaceuticalsLatest Information Update: 28 Nov 2018
At a glance
- Originator London Health Sciences Centre Research
- Developer Novare Pharmaceuticals
- Class Proteins
- Mechanism of Action Hyaluronic acid modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Arthritis; Bronchopulmonary dysplasia; Idiopathic pulmonary fibrosis; Keloids; Scars
Most Recent Events
- 28 Nov 2018 No recent reports of development identified for research development in Arthritis in USA
- 28 Nov 2018 No recent reports of development identified for research development in Bronchopulmonary-dysplasia in USA
- 28 Nov 2018 No recent reports of development identified for research development in Idiopathic-pulmonary-fibrosis in USA